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The basis of personalized medicine in oncology is the prediction of an individual’s risk of
relapse and death from disease. The presence of tumor budding (TB) at the tumor–host
interface of gastrointestinal cancers has been recognized as a hallmark of unfavorable dis-
ease biology.TB is defined as the presence of dedifferentiated cells or small clusters of up
to five cells at the tumor invasive front and can be observed in aggressive carcinomas of the
esophagus, stomach, pancreas, ampulla, colon, and rectum. Presence of TB reproducibly
correlates with advanced tumor stage, frequent lymphovascular invasion, nodal, and dis-
tant metastasis.The UICC has officially recognizedTB as additional independent prognostic
factor in cancers of the colon and rectum. Recent studies have also characterized TB as a
promising prognostic indicator for clinical management of esophageal squamous cell car-
cinoma, adenocarcinoma of the gastro-esophageal junction, and gastric adenocarcinoma.
However, several important issues have to be addressed for application in daily diagnostic
practice: (1) validation of prognostic scoring systems forTB in large, multi-center studies, (2)
consensus on the optimal assessment method, and (3) inter-observer reproducibility. This
review provides a comprehensive analysis of TB in cancers of the upper gastrointestinal
tract including critical appraisal of perspectives for further study.
Keywords: gastrointestinal cancer, gastric cancer, esophageal cancer, tumor microenvironment, tumor budding,
prognostic factor, epithelial–mesenchymal transition
INTRODUCTION
The foundation of personalized oncological therapy is the predic-
tion of an individual’s risk of relapse and death from disease. Stag-
ing of tumors is performed according to the AJCC/UICC TNM
classification (1). Following these internationally accepted guide-
lines, therapy decisions are made based on the anatomic extent
of the tumor as determined by clinical, radiographic, and patho-
logic staging. In carcinomas of the upper gastrointestinal tract, we
know that most patients with early invasive disease can expect a
good prognosis and consequently advocate surgical or endoscopic
resection as standard of care, while patients with locally advanced
tumors or nodal metastasis are treated with multimodality ther-
apy (2). Treatment decisions carry severe consequences for the
patient. Precise risk assessment is therefore of central importance
to balance benefit and overtreatment.
Following the TNM classification, patients with carcinomas of
the upper gastrointestinal tract can be assigned to one of five main
stages (1, 3). However, in the light of precision medicine and mol-
ecular pathology, risk stratification based only on the T, N, M,
L, V, and R classifiers has to be viewed as approximate. In can-
cers of the upper gastrointestinal tract, we know that unexpected
adverse clinical outcomes can be observed in patients even with
early-stage disease (4, 5). Additional prognostic indicators based
on tumor and host characteristics are therefore needed to find
a precision approach. In particular, tumor-related factors found
in the microenvironment may centrally impact patient prognosis.
Recent studies highlight that epithelial tumors undergo mesenchy-
mal transition (EMT) in the tumor microenvironment, allowing
dissociative growth, migration, and lysis of stromal components
(6–8). In carcinomas of the gastrointestinal tract, the visible cor-
relate of cells undergoing EMT is thought to be the presence
of single cells or small clusters of up to five cells in the tumor
stroma ahead of the invasive front, termed tumor budding (TB)
(6, 7, 9, 10) (Figure 1). It is important to note that tumor buds
can be quantified on the histologic slide to provide a TB score,
which correlates with tumor aggressiveness. The prognostic value
of TB has been established in a large number of independent ret-
rospective studies for squamous cell carcinoma (SCC) (11–15)
and adenocarcinoma of the esophagus (16–19), stomach (20, 21),
colon (22–25), and rectum (26–29). Importantly, TB is officially
recognized as an additional prognostic factor by the UICC for col-
orectal cancer and is listed by the European (30) and Japanese (31)
guidelines for colorectal cancer screening and diagnosis as well
as the guidelines of the European Society for Medical Oncology
(ESMO) (32). Further, TB has recently been listed as a non-core
data item by the European consensus conference colon and rec-
tum (EURECCA), highlighting the increased use of this feature in
clinical practice (33).
Biologically, tumor buds may transiently acquire a mesenchy-
mal phenotype due to loss of E-cadherin expression and nuclear
translocation of β-catenin leading to activation of WNT signaling
(6, 34). Upregulation of metalloproteinases, urokinase receptor,
and cathepsin may contribute to an increased migratory capac-
ity and stromal invasion (35, 36). It has been suggested that
tumor buds may resist both apoptosis and anoikis following
the detachment from the primary tumor due to upregulation
of anti-apoptotic proteins such as RAF-kinase inhibitor protein
(RKIP) and caspase-3 deficiency (37–39). Further, tumor buds
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FIGURE 1 |Tumor budding. (A) High-power image (250×) of tumor
budding at the invasive front of colorectal cancer as visualized by
pancytokeratin (brown) immunohistochemistry. (B) Tumor buds as seen in a
standard hematoxylin and eosin (H&E) stain (250×).
exhibit a low proliferative activity, which is in line with their
migratory phenotype (38, 40). Taken together, these features may
explain an increased resistance of tumor buds to chemo- and
radiotherapy. Indeed, high-grade TB has been shown to be a highly
specific indicator of poor response to radiotherapy in rectal cancer
patients (41). As immunogenic cell death also entails the induc-
tion of apoptosis, this may also indicate an increased resistance
to immunotherapeutic agents. Few studies have investigated the
immunogenicity of tumor buds, but it has been suggested that
loss of MHC-I expression could be a frequent feature in can-
cer initiating cells (42). CD8+ T-cells are frequent in the tumor
microenvironment (43), yet may not be able to efficiently recog-
nize tumor buds if MHC-I is lost. Interestingly, tumor buds may
also possess stem cell like features, as suggested by an increased
expression of ABCG-5 protein (44). These stem cell characteristics
may allow cancer initiation at distant sites (Figure 2).
The formation of tumor buds by solid tumors may therefore
represent an important first step toward metastasis. Interestingly,
the histopathologist can visualize this step and make this feature
accessible as a prognostic indicator for clinical management. In
comparison to tumor grade, which has shown poor inter-observer
reproducibility, the quantitative assessment of TB holds a defi-
nite advantage, just as mitoses are counted within a defined visual
field for the histopathological reporting of the BRE-score score
FIGURE 2 |Tumor budding leads to vascular invasion and metastasis.
The formation of tumor buds is thought to be the visible correlate of
epithelial–mesenchymal transition (EMT) in the tumor microenvironment.
Following tumor cell dissociation, lymphovascular invasion is frequently
observed in high-grade budding tumors. TB could be a source of circulating
cancer cells (CICs), leading to the establishment of metastasis at distant
sites in the process of mesenchymal–epithelial transition (MET).
in breast cancer, tumor buds can be directly quantified under
the microscope and reported as a quantitative feature. However,
a broad spectrum of methods has been recommended for the
assessment of TB in daily diagnostic practice. Morodomi (45)
and Hase (46) have proposed a qualitative assessment based on
the observers’ impression of TB as present or absent (Morodomi),
none/mild or moderate/severe (Hase). Nakamura and colleagues
recommend semi-quantitative assessment of the proportion of the
invasive front with TB (23, 47). This highly subjective methodol-
ogy is contrasted by quantitative scoring methods as illustrated by
Ueno (22, 48), Wang (24), Ono (49), Park (50), Lugli (51), Ohike
(52), and Karamitopoulou (25). A central advantage to counting
tumor buds is that quantitative scores tend to have a much higher
inter-observer reproducibility (53) (Table 1).
Taken together, high-grade TB in gastrointestinal carcino-
mas could be a general indicator of aggressive clinicopatho-
logical behavior with importance for individualized risk assess-
ment. While many studies have addressed TB in colon and rectal
carcinoma, a uniting perspective on TB in carcinomas of the upper
gastrointestinal tract has so far not been attempted. Subject of
this review is therefore to provide a comprehensive overview on
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Table 1 | Methods used for assessment of tumor budding.
Reference Method Classification Staining Region Area
Morodomi et al.,
1989 (45)
Qualitative; subjective assessment of TB intensity Present or absent H&E Invasive front Entire invasive front
Hase et al., 1993 (46) Qualitative; subjective assessment of TB intensity None/mild (BD-1) H&E Invasive front Entire invasive front
Moderate/severe (BD-2)
Ono et al., 1996 (49) Quantitative; all cancer cells with a single or
solitary trabecular form with indistinct polarity
(“focal dedifferentiation units”) counted along the
invasive front (200×)
None (0 unit)
Mild (1–20 units)
Moderate (21–50 units)
Severe (>50 units)
H&E Invasive front Entire invasive front
Nakamura et al.,
2005 (47)
Semi-quantitative assessment of the proportion
of the invasive front with TB
None, mild (<1/3 with TB)
Marked (>2/3 with TB)
H&E Invasive front Entire invasive front
Moderate (1/3–2/3 with TB)
Park et al., 2005 (50) Quantitative assessment of TB; the number of
buds is counted in three fields assessed under
high-power (200×) in area of most intense TB
along invasive front. TB intensity is defined as
maximum number of buds within the three fields
Continuous score H&E Invasive front Entire invasive front
assessed under low
power, 1 field (200×)
counted
Nakamura et al.,
2008 (23)
Semi-quantitative assessment of the proportion
of the invasive front with TB
None/mild (low-grade)
Moderate/marked
(high-grade)
H&E Invasive front Entire invasive front
Ueno et al., 2002
(48)
Quantitative; invasive front scanned at low power
to identify region with densest TB; buds are
counted in one HPF
Low-grade (<10 buds)
High-grade (≥10 buds)
H&E Invasive front 0.385 mm2
Ueno et al., 2004
(22)
Quantitative; invasive front scanned at low power
to identify region with densest TB; buds are
counted in one HPF
Low-grade (<5 buds)
High-grade (≥5 buds)
H&E Invasive front 0.785 mm2
Wang et al., 2009
(24)
Conventional method: quantitative; invasive front
scanned at low power to identify region with
densest TB; buds are then counted in 5
high-power fields
Low-grade (<50% of HPFs
exceed the median bud
count of all fields)
High-grade (≥50% of
HPFs exceed the median
bud count of all fields)
H&E Invasive front 0.94985 mm2
Wang et al., 2009
(24)
Rapid method: quantitative; 5 HPFs are evaluated
for presence of TB
Low-grade (<50% of HPFs
examined positive for TB)
H&E Invasive front 0.94985 mm2
High-grade (≥50% of HPFs
examined positive for TB)
Lugli et al., 2009
(1HPF method) (51)
Quantitative; 1 HPF counted in areas of
densest TB
Low-grade (<10 buds in 1
HPF of highest density)
PanCK Invasive front 0.49 mm2
High-grade (≥10 buds in 1
HPF of highest density)
Ohike et al., 2010
(52)
Semi-quantitative; budding foci are identified.
Buds are counted in one HPF of each focus as
specified by Ueno (48). A HPF is counted as
positive for TB when 5 or more tumor buds are
present
Low budding (0–2 positive
fields)
High budding (three or
more budding fields)
H&E Invasive front 0.785 mm2/HPF
(Continued)
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Table 1 | Continued
Reference Method Classification Staining Region Area
Karamitopoulou
et al., 2013 (10HPF
method) (25)
Quantitative; 10 HPF counted in areas of
densest TB
Low-grade (<100 buds
total in 10 HPFs of highest
density)
High-grade (≥100 buds
total in 10 HPFs of highest
density)
PanCK Invasive front 0.49 mm2/HPF for a
total area of 4.9 mm2
Landau et al., 2014
(19)
Semi-quantitative; 5 HPFs are evaluated for
presence of TB; A HPF is counted as positive for
TB when 5 or more tumor buds are present
No budding (no budding
fields)
Focal budding (one to two
budding fields)
H&E Invasive front 0.785 mm2/HPF
Extensive budding (three
or more budding fields)
TB, tumor budding; HPF, high-power field; H&E, hematoxylin and eosin; PanCK, pancytokeratin.
TB as a novel and promising tumor-related histomorphological
prognostic factor in cancers of the esophagus and stomach.
METHODS
The focus of this work was to review the primary and secondary
literature on TB in upper gastrointestinal carcinomas. Electronic
keyword searches using Boolean operators were performed to
identify relevant primary sources in the following databases: MED-
LINE, MEDLINE In Process, Scopus, Web of Science, EMBASE,
Google Scholar, and ISI Proceedings. Manual searches were per-
formed of the reference lists. Searches were not limited by date
and include all literature published up to the 1st of July, 2014.
Case reports or notes were excluded. All identified studies were
reviewed and assessed for relevance. Data from relevant publica-
tions were extracted and categorized according to tumor type and
location. Data extraction tables were reviewed by all four authors
of this manuscript.
TUMOR BUDDING IN CARCINOMAS OF THE ESOPHAGUS
AND STOMACH
ESOPHAGEAL CARCINOMA
Carcinomas of the esophagus are the sixth most common malig-
nancy worldwide in males and the fifth most common cause
of death (15). Esophageal cancer occurs in two major histo-
logical types: SCC most frequently arises in the upper esoph-
agus and accounts for up to 90% of esophageal carcinomas in
developing countries (1). Esophageal adenocarcinoma, frequently
originates from pre-malignant Barrett Mucosa (“Barrett’s carci-
noma”), occurs in the lower third of the esophagus and has rapidly
increased in incidence in developed countries over the last decades
(1). Advances in early detection and multimodality therapy have
increased survival rates of patients with esophageal cancers mak-
ing histopathological risk stratification an important tool for
therapeutic decision making. This applies both to early cancers
of the esophagus, which can be treated by endoscopic mucosal
resection (EMR), radiofrequency ablation, or limited resection
(Merendino’s procedure) as well as advanced disease requiring
neo-adjuvant chemotherapy and esophagectomy.
Tumor budding as histomorphological prognostic factor in
squamous cell carcinoma of the esophagus
In SCC of the esophagus, TB has been evaluated for risk strati-
fication in different clinical settings (Table 2). In an analysis of
56 patients with surgically resected esophageal SCC of stages I–
III, high-grade TB was identified by Roh and colleagues in 60.7%
of cases (11). Increased TB predicted more advanced pT-stage,
lymphovascular invasion (LVI), perineural invasion, larger tumor
size, and circumferential resection margin involvement. Further,
patients with high-grade TB had a reduced 3-year survival out-
come of 30.7% after esophagectomy in comparison to 72.3% in
patients with low-grade budding. These findings are supported
by two subsequent publications [Ref. (12), n= 136; (14), n= 82],
which describe high-grade TB in 56.1–60.2% of patients under-
going esophagectomy for stage I–IV esophageal SCC (12, 14).
Even though both authors included a significant subset of patients
receiving pre-operative and/or adjuvant chemotherapy, both stud-
ies independently confirm TB as an indicator of poor survival
outcome with 5-year survival rates of 35.0–35.4% in patients with
high-grade TB as compared to 81.3–86.9% in absence of this fea-
ture. Further, high-grade TB consistently predicted more advanced
T-stage and lymph node metastasis (12, 14). Miyata and associates
addressed TB in the neo-adjuvant setting using a cohort of 74
stage II–IV patients. Interestingly, TB was also found to be a use-
ful prognostic indicator in patients who received neo-adjuvant
chemotherapy followed by surgery for advanced esophageal SCC
(13). In particular, the 5-year survival rate of patients with high-
grade TB in the resection specimen was 17%, compared with 49%
for those with low-grade TB. Further, TB correlated significantly
with a poor clinical chemotherapy response.
Moreover, TB was confirmed as a decisive prognostic indicator
in surgically treated early-stage esophageal SCC in a recent study
including 79 pT1 patients by Teramoto and colleagues (15). In
these early-stage patients, only 36.7% showed high-grade TB while
63.3% were assigned to the low-grade budding group; this data
suggest that TB may be less frequently encountered in patients with
limited disease. Following esophagectomy, the investigators report
3-year survival rates of 48.8% for pT1 patients with high-grade TB
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Table 2 | Studies on tumor budding as a histomorphological prognostic factor in squamous cell carcinoma of the esophagus.
Reference Tumor
subtype
Stage N Treatment Method for
assessment
ofTuB
Low-grade/
high-grade
TB%
Correlation of high-grade
TB with clinicopathological
features (p<0.05)
Outcome
Roh et al.,
2004 (11)
SCC I–III 56 56/56 Patients were treated by
primary resection
Ueno et al., 2004
(22) H&E
39.3/60.7 T-stage, L1, Pn1, larger tumor size,
circumferential resection margin
involvement, advanced AJCC-stage
3-year survival rates after esophagectomy
with low-grade TB: 72.3%; high-grade TB:
30.7% (p=0.04)
Koike et al.,
2008 (12)
SCC I–IV 136 82/136 Patients received
pre-operative CTX- and/or RTX
52/139 Patients received adjuvant
CTX- and/or RTX
Ueno et al., 2004
(22) H&E
39.8/60.2 T-stage, N-stage, L1, increased invasion
depth, larger tumor size, intramural
metastasis
5-year survival rates after esophagectomy
with low-grade TB: 35.4%; high-grade TB:
81.3% (p=0.001)
Miyata
et al., 2009
(13)
SCC II–IV 74 74/74 Patients received
pre-operative CTX
Ueno et al., 2004
(22) H&E
59/41 Not analyzed 5-year survival rates after esophagectomy
with low-grade TB: 49%; high-grade TB:
17% (p<0.001)
Nakanishi
et al., 2011
(14)
SCC I–IV 82 82/82 Patients were treated by
primary resection
22/82 Patients received adjuvant
CTX
Ueno et al., 2004
(22) PanCK
43.9/56.1 T-stage, N-stage, L1, V1, larger tumor
size
Disease-free survival time in patients with
low-grade TB: 113 months; in patients with
high-grade TB: 31 months (p<0.0001)
Teramoto
et al., 2013
(15)
SCC I 79 73/79 Patients were treated by
primary resection
6/79 Patients were treated by EMR
followed by radical surgery
Modified Ueno
et al., 2004 (22)
H&E
63.3/36.7 N-stage, L1, V1, tumor differentiation,
increased invasion depth
3-year survival rates after esophagectomy
with low-grade TB: 94.5%; High-grade TB:
48.8% (p<0.001)
11/79 Patients received adjuvant
CTX- and/or RTX
TB, tumor budding; SCC, squamous cell carcinoma; AC, adenocarcinoma; CTX, chemotherapy; RTX, radiotherapy; H&E, hematoxylin and eosin; PanCK, pancytokeratin; V1, venous invasion; L1, lymphatic invasion;
Pn1, perineural invasion.
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as compared to 94.5% in the absence of this feature. Within the
cohort, 11 patients received adjuvant therapy.
In summary, these studies support the use of TB as a use-
ful histomorphological prognostic factor for primarily resected
esophageal SCC, in the neo-adjuvant setting and in early-stage
cancers of the esophagus. The validation of TB as a histomorpho-
logical prognostic factor in squamous cell esophageal cancer in
large multi-centric studies is therefore recommended.
Tumor budding as histomorphological prognostic factor in
adenocarcinoma of the esophagus
Four studies were identified following a literature search exam-
ining TB in AC of the esophagus or gastro-esophageal junction
(Barrett’s carcinoma) (Table 3). In a well-designed, two-center ret-
rospective study including 287 cases of stage I–IV esophageal AC
and 69 cases of SCC by Brown and associates, high-grade TB was
associated with a median overall survival outcome of 15 months
while patients with low-grade TB reached 31 months (16). Impor-
tantly, TB retained prognostic significance in both the AC and
SCC subgroup (p= 0.0001 and p= 0.021, respectively), when
including neo-adjuvant therapy (n= 115/356 patients; p= 0.003)
and in multivariable analysis with age, N -stage, and overall-stage
(p= 0.002). Further, high-grade TB was associated with higher
overall TNM-stage and adverse clinicopathological features such
as lymph node metastasis, poor tumor differentiation, and incom-
plete excision. However, no separate analysis of SCC and AC was
attempted concerning TNM-relevant clinicopathological features.
Of note, a recent study presented at the Annual Meeting of the Ger-
man Society of Pathology confirmed the association of TB with
aggressive histopathology of esophageal and GI-junction AC on
an independent set of 86 stage I–IV patients treated by primary
resection (17). In particular, high-grade TB correlated significantly
with advanced T-stage, higher tumor grade, non-intestinal/diffuse
histological subtype, and higher rates of R1-resection. Survival
analysis showed a trend toward poor overall survival in patients
with high-grade TB but did not reach statistical significance,
possibly due to the relatively small number of patients under
study.
Two independent studies specifically address the prognostic
impact of TB in early-stage AC of the esophagus. In 42 patients
with surgically treated pT1 AC, Nowak and colleagues demonstrate
a significantly increased rate of tumor recurrence and nodal metas-
tasis with high-grade TB (18). Further, high-grade TB predicted
a high risk for adverse survival outcome (HR= 3.06; p= 0.015).
These results were recently expanded in a well-designed retrospec-
tive analysis by Landau et al. for 210 surgically resected pT1 AC
of the esophagus (19). The authors identify a significant corre-
lation between TB-grade and submucosal invasion. In fact, 95%
of tumors with extensive TB invaded the superficial (pT1a) or
deep submucosal layer (pT1b) as compared to 54% of cases with
none or focal TB (p< 0.001). Further, extensive TB correlated
strongly with aggressive histopathological features, including poor
tumor differentiation, angioinvasion, and larger tumor size (all
p< 0.001). Even though the overall outcome is favorable in pT1
patients, Landau and colleagues report a survival rate of only 37%
of patients with extensive TB at 5 years follow-up as compared
to 79% in absence of this feature (p< 0.0001). In multivariable
analysis, the negative prognostic impact of TB (HR 3.3; 95% CI:
1.5–7.4; p= 0.004) was found to be independent of submucosal
invasion depth, N-stage, patient age, and type of surgery. Simi-
lar results were observed for tumor recurrence at 24 months after
surgery; while only 5% of patients without TB relapsed, tumor
recurrence was found in 19% of those with focal TB and 36%
of patients with extensive TB (p< 0.0001). This was independent
of both T- and N-stage in multivariable analysis (HR= 3.2; 95%
CI= 1.4–7.0).
Taken together, these studies indicate that TB may be a valu-
able predictor of aggressiveness of disease in esophageal AC. Early
esophageal carcinoma with lamina propria (pT1a) or submucosal
invasion (pT1b) not infrequently take a detrimental course as a
consequence of micrometastasis already present at the time of
resection (54). EMR is an increasingly popular treatment option
for the early-stage subgroup. Precise risk assessment in the sur-
gical pathology practice is therefore of crucial importance for
clinical management of early-stage AC. In locally advanced AC
of the esophagus, TB in the resection specimen may serve as a
valuable prognostic indicator to guide clinical follow-up. Large,
multi-centric studies including robust statistical analysis are there-
fore recommended to validate the prognostic impact of TB in the
clinical management of esophageal AC.
Future outlook
Opportunities for further study of TB seem abundant in
esophageal cancer, as several important factors are unique to the
assessment of histomorphological biomarkers – and particularly
TB – in this disease. First, SCC is common in the esophagus but
very rare in other locations of the GI-tract. As TB was initially
defined as a histomorphological prognostic factor in the microen-
vironment of AC of the colon and rectum, the need of a systematic
comparison of the biological characteristics of tumor buds in SCC
of the esophagus and AC of the GI-tract is evident. A conserved
pattern of features related to the process of EMT would further
support the notion of tumor buds as histomorphological hallmark
of aggressive disease biology in the tumor microenvironment.
Second, multimodality treatment strategies for esophageal can-
cers differ from cancers of the stomach and colorectum. While
presence of TB in the surgically resected specimen of CRC may be
an indicator of aggressive disease requiring adjuvant chemother-
apy, esophageal cancers are commonly treated in the neo-adjuvant
setting where no information on budding activity in the tumor
microenvironment based on a resection specimen will be available.
Consequently, novel predictive factors based on biopsy material of
esophageal cancers are needed that could aid risk stratification
in conjunction with imaging and clinical findings. Interestingly,
intra-tumoral budding (ITB) may represent a novel prognostic
feature present in pre-operative biopsies of cancers of the GI-tract,
particularly of the colorectum (41, 55, 56). Based on the consistent
association of TB with aggressive histomorphological features in
both AC and SCC, investigation of ITB in esophageal carcinomas
may be expected to provide similar information.
Third, no agreement on the optimal approach to assess TB in
esophageal cancer has been found. For the visualization of TB, two
studies using cytokeratin staining were identified (14, 17), while
the remaining studies are based on standard H&E staining (11–13,
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Table 3 | Studies on tumor budding as a histomorphological prognostic factor in adenocarcinoma of the esophagus.
Reference Tumor
subtype
Stage N Treatment Method for
assessment
ofTuB
Low-grade/
high-grade
TB%
Correlation of high-grade
TB with clinicopathological
features (p<0.05)
Outcome
Brown
et al., 2010
(16)
AC/SCC I–IV Total: 356
69 SCC
287 AC
241/356 Patients treated
by primary resection
115/356 Patients received
pre-operative CTX
Ueno et al.,
2004 (22) H&E
48.3/51.7 T-stage, N-stage, poor tumor
differentiation, circumferential
resection margin involvement,
higher overall TNM-stage, low
inflammatory response. No
separate analysis of SCC and AC
was performed.
Low-grade TB: OS 31 months;
high-grade TB: OS 15 months
(p<0.0001)
Prognostic impact of TB is
independent of histologic type
(SCC, p=0.021; AC, p=0.0001),
age, N-stage, overall stage
Thies et al.,
2013 (17)
AC I–IV 86 86/86 Patients were
treated by primary
resection
Karamitopoulou
et al., 2013
(25) PanCK
60.5/39.5 pT-stage, higher tumor grade,
non-intestinal/diffuse histological
subtype, higher rates of
R1-resection
Survival analysis showed a trend to
worse survival for high-grade TB
(p=0.15; ITB p=0.13)
Nowak
et al., 2013
(18)
AC I 42 42/42 Patients were
treated by primary
resection
Adapted Ueno
et al., 2004
(22) H&E
Not specified N-stage High-grade TB was a strong
predictor of tumor recurrence
(HR=14.21; p=0.022) and
reduced OS (HR=3.06; p=0.015)
Landau
et al., 2014
(19)
AC I esophageal
AC or AC of
gastro
esophageal
junction
210 210/210 Patients were
treated by primary
resection
Ueno et al.,
2004 (22) H&E
adapted
according to
Ohike et al.,
2010 (52)
Any TB: 44.3%
focal: 16%
extensive 28% no
TB: 55.7%
N-stage, submucosal invasion
depth, grade, angioinvasion,
tumor size
5-year OS: no TB: 79%, focal TB:
71%, extensive TB: 37% (p>0.001)
Multivariate analysis: HR for death
(extensive TB): 3.3 (95%
CI=1.5–7.4, p=0.004);
independent of T- and N-stage, age,
type of surgery
Disease recurrence at 24 months:
no TB: 5%, focal TB: 19%, extensive
TB: 36%
Multivariate analysis: HR for
recurrence (extensive TB): 3.3 (95%
CI=1.4–7.0, p=0.005);
independent of T- and N-stage
TB, tumor budding; SCC, squamous cell carcinoma; AC, adenocarcinoma; CTX, chemotherapy; RTX, radiotherapy; H&E, hematoxylin and eosin; PanCK, pancytokeratin; V1, venous invasion; L1, lymphatic invasion;
Pn1, perineural invasion; OS, overall survival.
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15, 16, 18, 19). Methodologically, TB in esophageal SCC has been
assessed in one densest high-power field (HPF, 200×) according
to Ueno (22) by eight authors with variable modifications. Other
authors have used the scoring approach suggested by Ohike (52)
and the 10 HPF methods (25) (Tables 2 and 3). Only one study
was identified assessing inter-observer variability for TB using a
10 HPF approach (17). Consequently, a systematic inter-observer
study comparing different methods for the assessment of TB seems
desirable both in SCC and AC to reach consensus on the optimal
approach for daily diagnostic practice.
GASTRIC ADENOCARCINOMA
Gastric cancer is among the five most frequent cancers in males and
females worldwide with an estimated 738,000 deaths in 2011 (15).
Gastric AC occurs in two major histological subtypes according
to the Lauren classification, intestinal, and diffuse (1). As stan-
dard of care, operable patients with stage II–III disease are treated
with multimodality therapy following resection (57–59). For stage
IB patients with node positive (T1 N1) and muscle invasive dis-
ease (T2 N0) the role of adjuvant chemotherapy is less clear. Even
though the prognosis of early-stage patients is relatively favorable
following complete resection of the primary tumor, individual
patients may follow an aggressive clinical course characterized by
local and distant disease recurrence (60). Additional prognostic
factors such as TB may be particularly helpful for risk stratification
in this setting to identify patients that may profit from multimodal
treatment following resection.
Tumor budding as an adverse histomorphological prognostic factor
in gastric adenocarcinoma
Literature analysis of TB in gastric AC identified only two stud-
ies from independent centers (Table 4). In 1992, Gabbert and
colleagues analyzed the prognostic significance of tumor cell dis-
sociation (TCD) at the invasive front of gastric AC in a cohort
of 445 surgically treated stage I–IV patients (20). Even though
TCD is not termed TB by the authors, the quantitative assessment
of this feature is clearly very closely related to TB as described
by Hase and colleagues (46) with TCD grades 0/1 correspond-
ing to absent/mild TB and TCD grade 2/3 to moderate/severe TB.
TCD grade 2/3 was found in 51.7% of patients. Interestingly, the
degree of TCD at the invasive front predicted aggressive disease
with 5-year survival of 38.5% in comparison to 92.3% in patients
with absence of this feature, independently of T-stage, tumor size,
and grade (p= 0.026). Further, patients with high-grade TCD fre-
quently presented with more advanced T-stage, N-stage, vascular
invasion, high-grade tumors, and larger tumor size.
In a recently published study, Tanaka et al. address TB in a well
characterized retrospective cohort of 320 surgically treated stage I–
IV gastric AC patients including 161 patients receiving adjuvant or
palliative chemotherapy following resection (21). High-grade TB
was observed in 60.0% of cases, a similar frequency as reported by
Gabbert (20). Importantly, high-grade TB correlated significantly
with TNM-relevant features including T-stage, N-stage, lymphatic
invasion as well as synchronous liver metastasis and distant metas-
tasis. Further, high-grade TB was associated with larger tumor size
and depressive macroscopic morphology. In patients with pre-
dominantly differentiated histology (n= 153), TB was found to Tab
le
4
|S
tu
d
ie
s
o
n
tu
m
o
r
b
u
d
d
in
g
as
a
h
is
to
m
o
rp
h
o
lo
g
ic
al
p
ro
g
n
o
st
ic
fa
ct
o
r
in
ga
st
ri
c
ad
en
o
ca
rc
in
o
m
a.
R
ef
er
en
ce
Tu
m
o
r
su
b
ty
p
e
S
ta
ge
N
Tr
ea
tm
en
t
M
et
h
o
d
fo
r
as
se
ss
m
en
t
o
fT
u
B
Lo
w
-g
ra
d
e/
h
ig
h
-g
ra
d
e
T
B
%
C
o
rr
el
at
io
n
o
f
h
ig
h
-g
ra
d
e
T
B
w
it
h
cl
in
ic
o
p
at
h
o
lo
g
ic
al
fe
at
u
re
s
(p
<
0.
05
)
O
u
tc
o
m
e
G
ab
be
rt
et
al
.,
19
92
(2
0)
A
C
I–
IV
44
5
44
5/
44
5
Pa
tie
nt
s
tr
ea
te
d
by
pr
im
ar
y
re
se
ct
io
n
U
en
o
et
al
.,
20
04
(2
2)
H
&
E
48
.3
/5
1.
7
T-
st
ag
e,
N
-s
ta
ge
,t
um
or
gr
ad
e,
ci
rc
um
fe
re
nt
ia
lr
es
ec
tio
n
m
ar
gi
n
in
vo
lv
em
en
t
O
S
31
m
on
th
s
in
pa
tie
nt
s
w
ith
lo
w
-g
ra
de
TB
;O
S
15
m
on
th
s
in
pa
tie
nt
s
w
ith
hi
gh
-g
ra
de
TB
(p
<
0.
00
01
)
Ta
na
ka
et
al
.,
20
14
(2
1)
A
C
I–
IV
32
0
32
0/
32
0
Pa
tie
nt
s
tr
ea
te
d
by
pr
im
ar
y
re
se
ct
io
n
11
1/
32
0
Pa
tie
nt
s
re
ce
iv
ed
ad
ju
va
nt
C
TX
50
/3
20
Pa
tie
nt
s
re
ce
iv
ed
pa
lli
at
iv
e
C
TX
M
od
ifi
ed
K
ar
am
ito
po
ul
ou
et
al
.,
20
13
(2
5)
Pa
nC
K
40
.0
/6
0.
0
T-
st
ag
e,
N
-s
ta
ge
,L
1,
sy
nc
hr
on
ou
s
liv
er
m
et
as
ta
si
s,
ot
he
r
di
st
an
t
m
et
as
ta
si
s,
la
rg
er
tu
m
or
si
ze
,d
ep
re
ss
iv
e
m
ac
ro
sc
op
ic
m
or
ph
ol
og
y
H
ig
h-
gr
ad
e
TB
is
a
po
or
pr
og
no
st
ic
fa
ct
or
in
pa
tie
nt
s
w
ith
di
ffe
re
nt
ia
te
d
hi
st
ol
og
y
(n
=
15
3;
H
R
=
1.
61
;9
5%
C
I:
1.
12
–2
.4
1;
p
<
0.
01
)i
n
un
iv
ar
ia
te
an
al
ys
is
.N
ot
in
de
pe
nd
en
tly
pr
og
no
st
ic
in
m
ul
tiv
ar
ia
te
an
al
ys
is
.
TB
,t
um
or
bu
dd
in
g;
S
C
C
,s
qu
am
ou
s
ce
ll
ca
rc
in
om
a;
A
C
,a
de
no
ca
rc
in
om
a;
C
TX
,c
he
m
ot
he
ra
py
;R
TX
,r
ad
io
th
er
ap
y;
H
&
E
,h
em
at
ox
yl
in
an
d
eo
si
n;
Pa
nC
K
,p
an
cy
to
ke
ra
tin
;V
1,
ve
no
us
in
va
si
on
;L
1,
ly
m
ph
at
ic
in
va
si
on
;
P
n1
,p
er
in
eu
ra
li
nv
as
io
n;
O
S,
ov
er
al
ls
ur
vi
va
l.
Frontiers in Oncology | Gastrointestinal Cancers August 2014 | Volume 4 | Article 216 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Koelzer et al. Tumor budding in esophagogastric cancer
be an adverse prognostic indicator (HR= 1.61; 95% CI: 1.12–
2.41; p< 0.01) in univariate analysis. However, when including
other TNM-relevant features, TB did not retain prognostic sig-
nificance in multivariate analysis. Taken together, TB may be a
possibly highly prognostic feature that is clearly underrepresented
in studies of histomorphological features of gastric cancer.
Tanaka and colleagues also provide insight into the biolog-
ical processes that may contribute to the formation of tumor
buds in gastric AC. Using immunohistochemistry, geographic pro-
tein expression analysis of the pro-proliferative and pro-invasive
tropomyosin-related receptor kinase B (TrkB) in gastric carci-
nomas was performed. TrkB expression may promote EMT in
malignant cells and has been associated with chemotherapy resis-
tance of esophageal carcinomas (61, 62). In consistence with this,
Tanaka and colleagues report an increased frequency of TB in
patients with high TrkB expression at the tumor center, margin, or
invasive front. Tumor buds themselves frequently over-expressed
TrkB, confirming previous studies on this protein in tumor buds
of colorectal cancer (39). Consequently, over-expression of TrkB
expression may be a common feature of cells undergoing EMT
and may allow increased resistance to pro-apoptotic stimuli and
chemotherapeutic agents.
Future outlook
Data on the prognostic impact of TB in gastric AC is still sparse.
More data are needed to reliably judge the potential value of TB for
the clinical management and follow-up of gastric cancer patients.
Further, the impact of TB in the early-stage subgroup, in pre-
operative biopsy specimens and in the adjuvant setting has yet
to be addressed. To researchers interested in TB, gastric cancers
also pose a challenge due to the higher frequency of poorly dif-
ferentiated and signet cell carcinomas with a primary dissociative
growth pattern. It has so far not been explicitly addressed whether
gastric carcinomas or any other cancer of the GI-tract with a pri-
mary dissociative growth pattern should be defined as“high-grade
TB” (Figure 3A). As signet cell carcinomas of the stomach also
frequently display primary E-cadherin mutations, the use of this
feature to characterize cells undergoing EMT is limited (63). We
believe that differentiation of cancers with a primary dissociative
growth pattern from cancers with high-grade TB should therefore
be addressed on the base of morphology; the definition of TB as
the presence of single cells and small clusters of up to five dedif-
ferentiated tumor cells ahead of the invasive front implicates that
a solid tumor body must be present for bona fide TB to occur
(64) (Figure 3B). Clearly, the specific characteristics of TB in AC
of different histological type and differentiation require further
investigation.
CONCLUSION
Tumor budding is frequently observed in carcinomas of the upper
gastrointestinal tract. It is a valuable tumor-related prognostic
factor and indicator of aggressive disease biology. In esophageal
and gastric carcinomas, presence of TB in the resection specimen
predicts unfavorable clinicopathological features and early disease
recurrence. Information on TB provided by the histopathologist
could be of particular value for personalized patient management
in two distinct clinical scenarios: first, information on TB could be
an important factor for risk stratification of patients with locally
invasive SCC or AC of the esophagus (15, 19). Consequently,
patients with high-grade TB may benefit from esophagectomy
FIGURE 3 |Tumor budding in Barrett’s carcinoma. (A) Poorly
differentiated adenocarcinoma of the esophagus with signet cell
component as seen in a pancytokeratin (top) and H&E (bottom)
stain (250×). Tumor buds cannot be differentiated by morphology
from the diffusely infiltrating tumor mass. (B) Intestinal type
adenocarcinoma of the esophagus with presence of tumor buds at
the invasive front as seen in a pancytokeratin (top) and H&E
(bottom) stain (250×).
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rather than treatment with locally ablative procedures. It is fair
to assume that assessment of TB in EMR specimens or pre-
operative biopsy material could provide important information
on the relative risk for lymph node metastasis and disease recur-
rence. Further studies are therefore of particular importance to
address this clinical scenario. Second, TB may be a valuable addi-
tional prognostic indicator to aid the selection of high risk patients
with esophageal cancer for multimodality therapy. In particular,
some patients with pT2 esophageal cancer present with early dis-
ease recurrence following resection of the primary tumor. In this
setting, TB may provide additional prognostic information for
personalized therapeutic approaches. However, a central limita-
tion to these applications for TB in the assessment of esophageal
and gastric cancers is still the relative scarcity of data. As com-
pared to colorectal cancer where TB is already officially recognized
as additional prognostic factor by the UICC (1), studies on TB
in upper gastrointestinal cancers are based on a limited patient
number and a small group of study centers. Large multi-centric
studies including robust statistical analysis are therefore urgently
needed to determine whether TB can assume a similar role in
upper gastrointestinal cancers.
Standardization of assessment methods is another central road-
block for the establishment of TB as histomorphological prog-
nostic factor in gastrointestinal pathology. This holds true for
carcinomas of the esophagus and stomach and also the colorec-
tum. In analogy to the BRE-score for breast cancer or the Gleason
score in prostate cancer, TB shows potential to assume an impor-
tant role for prognostication and therapy planning in GI-cancers.
Consequently, approaches for standardization should not be lim-
ited to one section of the GI-tract but the attempt to find consensus
should be made on an integrative basis. This requires agreement
on both qualitative and quantitative criteria.
For qualitative criteria, broad consent exists on the definition of
TB as single tumor cells or small clusters of up to five cells ahead of
the invasive front (65). The most widely used approach to visualize
this feature is a standard H&E stain, but expert opinion is variable
(19, 27, 66). In cases where strong inflammation is present at the
invasive front, differentiation of tumor buds from macrophages,
cell detritus, ruptured glands, and reactive stromal cells can be
challenging. Pancytokeratin immunohistochemistry has been rec-
ommended to better identify tumor buds in difficult cases and
may allow quantification of TB using digital imaging (66, 67).
For quantitative criteria, consensus on a reproducible approach to
define low or high-grade TB seems mandatory. A large number of
different methods have been suggested for the assessment of TB
in daily diagnostic practice, but systematic inter-observer stud-
ies are few. To provide evidence on the optimal methodological
approach to visualize TB, a systematic comparison of the inter-
observer reproducibility in large multi-centric studies is therefore
recommended.
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